HC Wainwright Issues Optimistic Estimate for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities researchers at HC Wainwright lifted their Q1 2026 EPS estimates for MiNK Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.77) per share for the quarter, up from their prior forecast of ($0.78). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($3.50) EPS, FY2027 earnings at ($3.58) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.12) EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14.

Separately, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MiNK Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

Shares of MiNK Therapeutics stock opened at $10.69 on Friday. The firm has a market cap of $53.13 million, a P/E ratio of -3.60 and a beta of 0.35. The firm’s 50-day simple moving average is $10.85 and its 200-day simple moving average is $12.20. MiNK Therapeutics has a twelve month low of $6.34 and a twelve month high of $76.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is currently owned by institutional investors and hedge funds.

MiNK Therapeutics News Roundup

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: MiNK will present investigator-initiated Phase II data on agenT-797 in combination with botensilimab and balstilimab at the AACR annual meeting (April 17–22). Positive or encouraging AACR data could drive renewed investor interest in the company’s solid-tumor program and partner-combination potential. MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
• Positive Sentiment: An abstract on agenT-797 was accepted for presentation at the ASGCT Annual Meeting (May). Acceptance at major scientific conferences raises visibility with researchers, potential collaborators and investors—helpful for a development-stage biotech seeking partnerships or licensing interest. MiNK Therapeutics’ AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $35 price target on INKT—continued buy-side coverage and a meaningful target can support investor confidence and act as a positive sentiment anchor. MiNK Therapeutics (NASDAQ:INKT) Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright updated several near-term EPS estimates (small upward revisions for Q1–Q3 2026 and FY2026–28), reflecting model-level adjustments rather than a change in recommendation; these tweaks marginally improve near‑term outlook but do not remove development risk. (No single linked article provided for the detailed estimate changes.)
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate slightly and materially cut its FY2029 estimate (from a positive $0.49 to ($0.12)), signaling longer‑term uncertainty in revenue/timing assumptions—this could weigh on valuation models that previously assumed later‑stage commercial upside.
• Neutral Sentiment: Trading remains light today compared with average volume and the stock sits well below its 12‑month high; until AACR/ASGCT data are public or a clear commercial path emerges, expect muted price action and higher sensitivity to headline risk.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.